|drug278||Artemesia annua Wiki||1.00|
|drug686||Camostat Mesilate Wiki||0.32|
|D007251||Influenza, Human NIH||0.29|
|D055370||Lung Injury NIH||0.18|
|D055371||Acute Lung Injury NIH||0.08|
There is one clinical trial.
The investigators decided to conduct a longitudinal study that compares the pulmonary tomographic patterns found in patients with viral pneumonia (i.e. influenza H1N1 and SARS-CoV-2) at a regional hospital. The primary aim of this study is to evaluate the association between the radiological CT pattern and the need for invasive mechanical ventilation. A secondary aim is to assess the mortality within the first 28 days of intensive care unit admission.
Description: Need for oral intubation within the first 10 days.Measure: Oral intubation Time: 10 days
Description: 28-day survival analysis using the Kaplan Meyer and Cox regression models.Measure: Survival Time: 28 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports